More than 1 out of 3 eligible Americans don't complete screening methods like colonoscopy or stool tests; a convenient blood draw could enhance detection during routine physicals.
The Shield blood test from Guardant shows limitations in early-stage cancer detection and misses 87% of precancerous growths, not positioned as a colonoscopy replacement.
#fda-approval #colorectal-cancer-detection #shield-blood-test #cancer-screening #medical-advancements
Collection
[
|
...
]